p.314 抽出テキスト

患者がほとんど(90%>)で,十分な鎮痛効果が得られていた(Wiffen 2016)。有害作用は,システマティックレビューの集計では,便秘,眠気,悪心,口渇,嘔吐があり(Wiffen 2014),1~2 割の患者が有害作用のため治療の変更が必要となる可能性があった(Wiffen 2017)。モルヒネを投与中は,同時に有害作用の治療を行う必要がある。したがって,がん疼痛(中等度から高度)のある患者に対して,モルヒネの投与を推奨する。

【引用文献】1) Flöter T, Koch EMW, Kap‒Cas study group. Comparison of two oral morphine formulations for chronic severe pain of malignant and nonmalignant origin. Clinical Drug Investigation 1997;14:183‒91 2) Melzack R, Mount BM, Gordon JM. The Brompton mixture versus morphine solution given orally:effects on pain. Can Med Assoc J 1979;120:435‒8 3) O’Brien T, Mortimer PG, McDonald CJ, et al. A randomized crossover study comparing the efficacy and tolerability of a novel once‒daily morphine preparation(MXL capsules)with MST Continus tablets in cancer patients with severe pain. Palliat Med 1997;11:475‒82 4) Vielvoye‒Kerkmeer A, Van Tinteren H, Mattern C, et al. Sustained release morphine in cancer pain. Eur J Palliat Care 2002;9:137‒40 5) Wilkinson TJ, Robinson BA, Begg EJ, et al. Pharmacokinetics and efficacy of rectal versus oral sustained‒release morphine in cancer patients. Cancer Chemother Pharmacol 1992;31:251‒4 6) Todd J, Rees E, Gwilliam B, et al. An assessment of the efficacy and tolerability of aʻdouble doseʼof normal‒release morphine sulphate at bedtime. Palliat Med 2002;16:507‒12 7) 武田文和,小川秀道,平賀一陽,他.癌患者の疼痛治療におけるPF‒402(硫酸モルヒネ持続性経口製剤)の臨床評価―硫酸モルヒネ徐放錠との比較.臨医薬1998;14:853‒69 8) Babul N, Provencher L, Laberge F, et al. Comparative efficacy and safety of controlled‒release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 1998;38:74‒81 9) Broomhead A, Kerr R, Tester W, et al. Comparison of a once‒a‒day sustained‒release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997;14:63‒73 10) Ridgway D, Sopata M, Burneckis A, et al. Clinical efficacy and safety of once‒daily dosing of a novel, prolonged‒release oral morphine tablet compared with twice‒daily dosing of a standard controlled‒release morphine tablet in patients with cancer pain:a randomized, double‒ blind, exploratory crossover study. J Pain Symptom Manage 2010;39:712‒20 11) Portenoy RK, Maldonado M, Fitzmartin R, et al. Oral controlled‒release morphine sulfate. Analgesic efficacy and side effects of a 100‒mg tablet in cancer pain patients. Cancer 1989; 63(Suppl 11):2284‒8 12) Mignault GG, Latreille J, ViguiéF, et al. Control of cancer‒related pain with MS Contin:a comparison between 12‒hourly and 8‒hourly administration. J Pain Symptom Manage 1995;10: 416‒22 13) Smith KJ, Miller AJ, McKellar J, et al. Morphine at gramme doses:kinetics, dynamics and clinical need. Postgrad Med J 1991;67(Suppl 2):S55‒9 14) Boureau F, Saudubray F, d’Arnoux C, et al. A comparative study of controlled‒release morphine(CRM)suspension and CRM tablets in chronic cancer pain. J Pain Symptom Manage 1992;7:393‒9 15) Hanks GW, Hanna M, Finlay I, et al. Efficacy and pharmacokinetics of a new controlled‒ release morphine sulfate 200‒mg tablet. J Pain Symptom Manage 1995;10:6‒12 16) Currow DC, Plummer JL, Cooney NJ, et al. A randomized, double‒blind, multi‒site, crossover, placebo‒controlled equivalence study of morning versus evening once‒daily sustained‒ release morphine sulfate in people with pain from advanced cancer. J Pain Symptom Manage 2007;34:17‒23 17) 水口公信,武田文和,平賀一陽,他.癌患者の痛みに対する塩酸モルヒネ坐剤AN‒631 の有用性の検討―硫酸モルヒネ徐放錠との比較.臨医薬1990;6:2357‒76 18) Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of

twenty‒four‒hourly Kapanol compared to twelve‒hourly MS Contin in the treatment of III章推奨